Compare Davita Inc (DVA) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Las Vegas Sands Corp. — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Las Vegas Sands Corp. trades at $44.86 (market cap $29.67B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.46% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | LVS | |
|---|---|---|
Market Cap | $14.92B | $29.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $69.49 |
52-Week Low | $103.87 | $44.78 |
Enterprise Value | $27.47B | $42.07B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
LVS trades at $45.90, down 1.69% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 revenue of $3.59 billion, up 25.3% year-over-year, and EPS of $0.91, beating estimates. Analyst consensus is strongly bullish with a $65.56 price target, though technical indicators show selling pressure near key support at $45.
LVS presents a compelling value opportunity with a P/E of 16.94 and consistent earnings beats, but faces headwinds from high debt levels and bearish technical momentum. Upside potential exists if the stock holds support and executes on growth, while downside risk persists if macroeconomic or regulatory pressures intensify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
